Public Equities L.P. Invus Acquires 29,747 Shares of Lexicon Pharmaceuticals, Inc. (LXRX) Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Public Equities L.P. Invus purchased 29,747 shares of the firm’s stock in a transaction that occurred on Friday, June 8th. The stock was bought at an average price of $12.89 per share, with a total value of $383,438.83. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

Public Equities L.P. Invus also recently made the following trade(s):

  • On Monday, June 11th, Public Equities L.P. Invus purchased 98,626 shares of Lexicon Pharmaceuticals stock. The stock was bought at an average price of $12.75 per share, with a total value of $1,257,481.50.
  • On Wednesday, June 6th, Public Equities L.P. Invus purchased 95,079 shares of Lexicon Pharmaceuticals stock. The stock was bought at an average price of $12.58 per share, with a total value of $1,196,093.82.
  • On Friday, June 1st, Public Equities L.P. Invus purchased 147,339 shares of Lexicon Pharmaceuticals stock. The stock was bought at an average price of $12.22 per share, with a total value of $1,800,482.58.
  • On Monday, June 4th, Public Equities L.P. Invus purchased 416,481 shares of Lexicon Pharmaceuticals stock. The stock was bought at an average price of $12.01 per share, with a total value of $5,001,936.81.
  • On Friday, May 25th, Public Equities L.P. Invus acquired 138,700 shares of Lexicon Pharmaceuticals stock. The shares were acquired at an average price of $9.62 per share, with a total value of $1,334,294.00.
  • On Wednesday, May 30th, Public Equities L.P. Invus acquired 433,378 shares of Lexicon Pharmaceuticals stock. The shares were acquired at an average price of $9.94 per share, with a total value of $4,307,777.32.

Shares of Lexicon Pharmaceuticals opened at $12.84 on Wednesday, according to MarketBeat. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -10.11 and a beta of 0.48. The company has a debt-to-equity ratio of 8.85, a current ratio of 2.72 and a quick ratio of 2.70. Lexicon Pharmaceuticals, Inc. has a one year low of $7.67 and a one year high of $18.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. The business had revenue of $25.21 million during the quarter, compared to analyst estimates of $25.30 million. Lexicon Pharmaceuticals had a negative return on equity of 213.32% and a negative net margin of 140.09%. The firm’s revenue was up 37.8% on a year-over-year basis. During the same period in the previous year, the company earned ($0.33) EPS. equities analysts expect that Lexicon Pharmaceuticals, Inc. will post -1.33 EPS for the current year.

Several institutional investors have recently made changes to their positions in the company. Aperio Group LLC lifted its holdings in shares of Lexicon Pharmaceuticals by 49.5% during the 1st quarter. Aperio Group LLC now owns 19,270 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 6,377 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Lexicon Pharmaceuticals by 3.2% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 226,635 shares of the biopharmaceutical company’s stock valued at $1,943,000 after buying an additional 7,078 shares during the last quarter. Quantitative Systematic Strategies LLC lifted its holdings in shares of Lexicon Pharmaceuticals by 61.4% during the 1st quarter. Quantitative Systematic Strategies LLC now owns 19,171 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 7,296 shares during the last quarter. LPL Financial LLC lifted its holdings in shares of Lexicon Pharmaceuticals by 34.1% during the 1st quarter. LPL Financial LLC now owns 29,172 shares of the biopharmaceutical company’s stock valued at $250,000 after buying an additional 7,426 shares during the last quarter. Finally, Jump Trading LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter valued at about $104,000.

LXRX has been the subject of a number of research reports. Wedbush raised their price objective on Lexicon Pharmaceuticals from $38.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, April 16th. JPMorgan Chase & Co. lowered Lexicon Pharmaceuticals from a “neutral” rating to an “underweight” rating and decreased their price objective for the stock from $15.00 to $10.00 in a research report on Wednesday, February 14th. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. Needham & Company LLC lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 23rd. Finally, BidaskClub upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 23rd. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $24.40.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Insider Buying and Selling by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply